Foghorn Therapeutics Inc FHTX.OQ FHTX.O is expected to show a fall in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
The Cambridge Massachusetts-based company is expected to report a 20.6% decrease in revenue to $6.197 million from $7.81 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Foghorn Therapeutics Inc is for a loss of 33 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 62.5% above its last closing price of $4.31
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.33 | -0.36 | -0.28 | Beat | 21.9 |
Mar. 31 2025 | -0.33 | -0.34 | -0.30 | Beat | 12.3 |
Dec. 31 2024 | -0.27 | -0.33 | -0.30 | Beat | 8.3 |
Sep. 30 2024 | -0.42 | -0.44 | -0.31 | Beat | 29.6 |
Jun. 30 2024 | -0.63 | -0.65 | -0.45 | Beat | 31.3 |
Mar. 31 2024 | -0.56 | -0.63 | -0.59 | Beat | 6.9 |
Dec. 31 2023 | -0.94 | -0.76 | -0.57 | Beat | 25.3 |
Sep. 30 2023 | -0.74 | -0.75 | -0.34 | Beat | 54.7 |
This summary was machine generated October 31 at 11:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)